At a glance

ClinicalIndex Comparison Record

Phase 1Completed· 26 enrolled

Drug / intervention

[C-11](R)-rolipramdrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00250172

NCT00250172Phase 1Completed

Compare CT.gov

PET Whole Body Biodistribution and Test Retest Brain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram

National Institute of Mental Health (NIMH)·interventional·Posted Nov 7, 2005·Updated Dec 16, 2019

In Brief

A Phase 1 clinical trial evaluating [C-11](R)-rolipram for Dosimetry and Healthy. Completed, enrolled 26 participants across 1 site.

Detailed Summary

The purpose of this study is to measure a particular protein in the brain called the phosphodiesterase by using the imaging techniques of positron emission tomography (PET) and magnetic resonance imaging (MRI). ...

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsDosimetry, Healthy

CountriesUnited States

Collaborators--

Timeline

Phase 1CompletedFinished

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartOct 2005

First PostedNov 2005

Primary CompletionFeb 2009

TodayJul 2026

First PostedNov 7, 2005

Enrollment StartOct 31, 2005

Primary CompletionFeb 5, 2009

TodayJul 2, 2026

Enrollment to primary: 3.3 yearsPosted 20.7 years ago

Interventions

[C-11](R)-rolipramdrug